Skip to main content Back to Top


Pentamidine Isethionate

Products Affected - Description

    • Pentamidine isethionate lyophilized powder for injection, Seton Pharmaceuticals, 300 mg, single dose vial, 10 count, NDC 13925-0515-10

Reason for the Shortage

    • Fresenius Kabi had Nebupent and Pentam 300 on back order due to a short-term manufacturer delay.
    • Seton Pharmaceuticals has pentamidine isethionate injection on shortage due to high demand.

Available Products

    • NebuPent lyophilized powder for inhalation, Fresenius Kabi, 300 mg, 15 mL single dose vial, NDC 63323-0877-15
    • Pentam 300 lyophilized powder for injection, Fresenius Kabi, 300 mg, single dose vial, 10 count, NDC 63323-0113-10

Estimated Resupply Dates

    • Seton Pharmaceuticals has pentamidine isethionate 300 mg vials for injection on allocation.

Implications for Patient Care

    • Some clinicians may choose to use Pentam off-label via the nebulized route or NebuPent via the injectable route because both products contain identical ingredients. NebuPent and Pentam are FDA approved for different indications.


Updated September 23, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created August 6, 2019 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins